Research map: Contemporary Real-World Treatment of Cardiac Transthyretin Amyloidosis with Tafamidis: A Long-Term Multicentre Study

Back to the article

Papers in this map

  1. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology · Roberto Miguel Lang · 2005 · 11389 citations · Cited by this paper
  2. Real-World Evaluation of Individualised Natriuresis and Diuresis Driven Protocol for Decongestion in Acute Heart Failure · 2026 · Related
  3. Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies · Peter C. Austin · 2010 · 4067 citations · Cited by this paper
  4. Cardiac amyloidosis with apical myocardial infarction: beyond the cherry on top · 2026 · Related
  5. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy · Matthew J. Maurer · 2018 · 2849 citations · Cited by this paper
  6. Interaction of secondary ventricular tricuspid regurgitation with RV in HFREF: an invasive pressure-volume loop study · 2026 · Related
  7. 2023 ESC Guidelines for the management of cardiomyopathies · Elena Arbelo · 2023 · 2720 citations · Cited by this paper
  8. Cost-effectiveness of TTVR with EVOQUE system in patients with Severe Tricuspid Regurgitation based on TRISCEND II trial · 2026 · Related
  9. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases · Pablo García‐Pavía · 2021 · 1229 citations · Cited by this paper
  10. FEV1 is a major prognostic factor in diverse heart failure populations: findings from the Global Heart Failure registry · 2026 · Related
  11. A new staging system for cardiac transthyretin amyloidosis · Julian David Gillmore · 2017 · 776 citations · Cited by this paper
  12. Frailty and Heart Failure: An Integrated Review of a Bidirectional Relationship · 2026 · Related
  13. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System · Martha A. Grogan · 2016 · 767 citations · Cited by this paper
  14. Left atrial remodelling and diastolic unloading after transcatheter tricuspid repair · 2026 · Related
  15. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis · Thirusha Lane · 2019 · 543 citations · Cited by this paper
  16. Premature stopping of LEIA-HF: protecting trial participants while preserving clinical knowledge · 2026 · Related
  17. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy · Julian David Gillmore · 2024 · 535 citations · Cited by this paper
  18. Unaccounted immunosuppression and absent donor data limit infection risk after high-urgency heart transplantation · 2026 · Related
  19. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure · Claire Raphael · 2006 · 476 citations · Cited by this paper
  20. Interplay Between Acute Heart Failure and COPD in Patients Hospitalized for Dyspnea: Prognostic Insights From the PARADISE Cohort · 2026 · Related
  21. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy · Marianna Fontana · 2024 · 449 citations · Cited by this paper
  22. Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years · Adam Ioannou · 2022 · 249 citations · Cited by this paper
  23. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis · Richard Kar-Hang Cheng · 2020 · 149 citations · Cited by this paper
  24. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness · Jose N. Nativi-Nicolau · 2021 · 125 citations · Cited by this paper
  25. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis · Alexios S. Antonopoulos · 2022 · 107 citations · Cited by this paper
  26. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis · Steven Law · 2022 · 65 citations · Cited by this paper
  27. Lower albumin levels are associated with frailty measures, trace elements, and an inflammation marker in a cross-sectional study in Tanushimaru · Maki Yamamoto · 2021 · 64 citations · Cited by this paper
  28. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey · Jose N. Nativi-Nicolau · 2021 · 62 citations · Cited by this paper
  29. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS) · Pablo García‐Pavía · 2024 · 54 citations · Cited by this paper
  30. Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy · Seiji Takashio · 2023 · 50 citations · Cited by this paper
  31. Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure · Ahmed Ghoneem · 2023 · 39 citations · Cited by this paper
  32. Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial · Kent Y. Feng · 2023 · 36 citations · Cited by this paper
  33. Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study · Philippe Debonnaire · 2024 · 33 citations · Cited by this paper
  34. Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018 · Svenja Ney · 2022 · 31 citations · Cited by this paper
  35. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population · Jamieson MacDonald Bourque · 2022 · 18 citations · Cited by this paper
  36. Real-World Characteristics and Treatment of Cardiac Transthyretin Amyloidosis: A Multicentre, Observational Study · Richard Julius Nies · 2024 · 14 citations · Cited by this paper
  37. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data · Maximilian Leo Müller · 2024 · 12 citations · Cited by this paper
  38. Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era · Maximilian Leo Müller · 2025 · 11 citations · Cited by this paper
  39. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval · Fabian aus dem Siepen · 2024 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)